A successful strategy in the development of antiretroviral drugs has been the targetting of the virally encoded reverse transcriptase (RT) (De Clercq, 1998; Artico, 1996). Two classes of compounds potently and selectively inhibit this enzyme: nucleoside and non-nucleoside reverse transcrip-tase inhi...
| Other Authors: | |
|---|---|
| Format: | Text |
| Language: | English |
| Subjects: | |
| Online Access: | http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.816.5630 http://avc.sagepub.com/content/12/1/37.full.pdf |
| id |
ftciteseerx:oai:CiteSeerX.psu:10.1.1.816.5630 |
|---|---|
| record_format |
openpolar |
| spelling |
ftciteseerx:oai:CiteSeerX.psu:10.1.1.816.5630 2023-05-15T15:25:32+02:00 The Pennsylvania State University CiteSeerX Archives application/pdf http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.816.5630 http://avc.sagepub.com/content/12/1/37.full.pdf en eng http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.816.5630 http://avc.sagepub.com/content/12/1/37.full.pdf Metadata may be used without restrictions as long as the oai identifier remains attached to it. http://avc.sagepub.com/content/12/1/37.full.pdf text ftciteseerx 2022-02-27T01:25:01Z A successful strategy in the development of antiretroviral drugs has been the targetting of the virally encoded reverse transcriptase (RT) (De Clercq, 1998; Artico, 1996). Two classes of compounds potently and selectively inhibit this enzyme: nucleoside and non-nucleoside reverse transcrip-tase inhibitors (NRTIs and NNRTIs, respectively). Both play an important role in the combination therapy for HIV infection/AIDS. To date, three NNRTIs are available for clinical use: nevirapine, delavirdine and efavirenz. However, new NNRTIs that show better activity against clinically rele-vant resistant mutants are needed. Since 1992, our group has been developing dihydro-alky- Text artico Unknown |
| institution |
Open Polar |
| collection |
Unknown |
| op_collection_id |
ftciteseerx |
| language |
English |
| description |
A successful strategy in the development of antiretroviral drugs has been the targetting of the virally encoded reverse transcriptase (RT) (De Clercq, 1998; Artico, 1996). Two classes of compounds potently and selectively inhibit this enzyme: nucleoside and non-nucleoside reverse transcrip-tase inhibitors (NRTIs and NNRTIs, respectively). Both play an important role in the combination therapy for HIV infection/AIDS. To date, three NNRTIs are available for clinical use: nevirapine, delavirdine and efavirenz. However, new NNRTIs that show better activity against clinically rele-vant resistant mutants are needed. Since 1992, our group has been developing dihydro-alky- |
| author2 |
The Pennsylvania State University CiteSeerX Archives |
| format |
Text |
| url |
http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.816.5630 http://avc.sagepub.com/content/12/1/37.full.pdf |
| genre |
artico |
| genre_facet |
artico |
| op_source |
http://avc.sagepub.com/content/12/1/37.full.pdf |
| op_relation |
http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.816.5630 http://avc.sagepub.com/content/12/1/37.full.pdf |
| op_rights |
Metadata may be used without restrictions as long as the oai identifier remains attached to it. |
| _version_ |
1766356155475427328 |